suggesting that it might normally represses the adaptive gene response profile associated with physiologic hypertrophy. Indeed, siRNA against C/EBP␤ in cultured neonatal cardiomyocytes or the hearts of C/EBP␤ϩ/-mice showed hypertrophy, increased proliferation, and a common profile of gene expression alterations that mimic exercise. 1 With respect to evolutionary conservation of this pathway, morpholinodirected knockdown of C/EBP␤ in Zebrafish increased cardiomyocyte cell number in the developing heart and affected expression of some genes similar to the exercise gene profiles observed in mice. Thus, starting with an unbiased genetic screen of a well-characterized physiologic state revealed a startling new insight relating to its molecular etiology.
A number of possible mechanisms were investigated to explain how C/EBP␤ might mediate this unique gene signature underlying adaptive cardiac hypertrophy. CITED4, another transcriptional cofactor that functions downstream of C/EBP␤, was shown to be directly upregulated in expression with reductions in C/EBP␤ levels. Indeed, CITED4 overexpression also induced myocyte proliferation in culture with similar changes in adaptive gene expression. 1 C/EBP␤ was also shown to directly interact with serum response factor (SRF) where it antagonizes SRF's effect on expression of genes involved in adaptive hypertrophy, such as GATA4 and ␣-myosin heavy chain (␣-MHC). The linkage with GATA4 is also mechanistically important because this transcription factor was shown to regulate cardiomyocyte proliferation and physiologic hypertrophy. 2, 3 Loss of SRF or GATA4 with GATA6 each also separately resulted in a complete loss of cardiomyocyte differentiation, 4, 5 suggesting that SRF, GATA4/6, and C/EBP␤ might function together as master regulators of physiologic growth and differentiation of cardiomyocytes.
Although C/EBP␤ was elegantly shown to function as a proximal mediator of exercise-related gene expression in the heart, a number of questions remain to be answered. First, C/EBP␤ is downregulated with exercise to permit induction of protective genes in the heart, such as GATA4. It will be important to elucidate the molecular pathway involved in downregulating C/EBP␤ mRNA expression in the heart during exercise stimulation. It will also be important to more definitively assess how C/EBP␤ might be linked with other known signaling pathways that mediate adaptive or exercise-induced hypertrophy. For example, insulin-like growth factor (IGF-1) stimulation of cardiomyocytes, which signals through phosphoinositol 3-kinase (PI3K)/Akt protein kinase, is a well-known pathway for programming adaptive cardiac growth. 6 Activation of extracellular signal-regulated kinases 1/2 (ERK1/2) also appear to be involved in adaptive cardiomyocyte growth. 7, 8 Analysis of this concept demonstrated a linkage with Akt signaling. Indeed, overexpression of Akt or dominant negative Akt in cultured cells decreased and increased C/EBP␤, respectively. 1 Exactly how PI3K/Akt signaling impacts C/EBP␤ is not know, nor is it known if ERK1/2 are involved, or the affects of other unrecognized pathways. It will also be important to understand how C/EBP␤ and CITED4 might control myocyte proliferation and the extent to which GATA4 is involved, or if other targets are more important. Related to this issue, it is not clear that cardiomyocyte number is actually increased in the hearts of C/EBP␤ heterozygous targeted mice or in wild-type mice subjected to exercise training, as the data only involved markers of myocyte cell cycle activity. More specifically, were there more myocytes in the adult hearts of exercised mice and how long after exercise would these new myocytes persist? With respect to the C/EBPϩ/-mice, are there only more cells during the developmental period or does the adult heart maintain greater myocyte content? Moreover, if there is a bonefide increase in total myocyte number in these hearts, is it mechanistically responsible for cardioprotection versus other conditioning effects (ie, greater capillary density, structural gene isoform switching, etc)? Finally, it may be interesting to investigate if C/EBP␤ plays a role in maladaptive cardiac hypertrophy or if it is truly specific to the adaptive response or physiologic response. For example, would C/EBP␤ overexpressing transgenic mice develop disease, or at the very least, would they resist exercise-induced adapta-tions? Similarly, would CITED4 overexpressing transgenic mice show physiologic hypertrophy as would be predicted, or would they display some disease manifestations?
